This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study of OSI-7904L as Treatment in Patients With Head and Neck Cancer Who Have Failed First-Line Therapy

This study has been completed.
Information provided by:
OSI Pharmaceuticals Identifier:
First received: June 30, 2005
Last updated: March 13, 2007
Last verified: March 2007
Multi-center, Phase II study to evaluate the efficacy and safety of OSI-7904Lin head and neck cancer in patients who have failed first-line therapy

Condition Intervention Phase
Locally Recurrent or Metastatic Cancer of the Head and Neck Must Have Failed First-Line Therapy Drug: OSI 7904L Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: A Phase II Study of Single-Agent OSI-7904L in Patients With Locally Advanced or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Have Failed First-Line Therapy

Resource links provided by NLM:

Further study details as provided by OSI Pharmaceuticals:

Estimated Enrollment: 85
Study Start Date: August 2004
Estimated Study Completion Date: August 2005

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Histologically or cytologically confirmed metastatic or locally recurrent SCCHN that is incurable with surgery or radiation therapy ECOG performance status 0-2 No more tha 1 prior chemotharapy regimen for metastatic or locally recurrent disease Adequate bone marrow, Hepatic and renal function. At least one target lesion greater than or equal to 20 mm.

Exclusion Criteria:

Symptomatic brain metasteses which are not stable, are not adequately controlled, are potenially life threatening or required radiation in the last 28 days Pregnant or lactating women. Concurrent anticancer therapy or other investigational drugs Patients with active or uncontrolled infections or other serious illnesses or medical conditions.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00116909

United States, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115
United States, New York
Stony Brook University Hospital
Stony Brook, New York, United States, 11794
United States, Tennessee
Sarah Cannon Cancer Center
Nashville, Tennessee, United States, 37203
The Vanderbilt Cancer Center
Nashville, Tennessee, United States, 37232
Sponsors and Collaborators
OSI Pharmaceuticals
  More Information Identifier: NCT00116909     History of Changes
Other Study ID Numbers: OSI-904-203
Study First Received: June 30, 2005
Last Updated: March 13, 2007

Additional relevant MeSH terms:
Neoplasm Metastasis
Head and Neck Neoplasms
Neoplastic Processes
Pathologic Processes
Neoplasms by Site processed this record on September 21, 2017